Impact of HR-HPV Infection on Oncological Outcomes in Early Cervical Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Sep 13

PMID 37700831

Authors

Xiaoqiang Su

Pan Liu

Hongwei Zhao

Lixin Sun

Wuliang Wang

Shuanglin Jin

Hui Wang

Ping Liu

Chunlin Chen

Min Hao

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the differences in long-term oncological outcomes between high-risk human papillomavirus (HR-HPV) negative and HR-HPV positive early-stage cervical cancers.

Methods: We retrospectively analysed 2061 cases of early-stage cervical cancer from the Chinese cervical cancer clinical diagnosis and treatment database. Kaplan-Meier curves were used to describe the survival outcomes of different HR-HPV infections. Cox proportional hazard regression model was used to analyze and determine independent risk factors.

Results: K-M analysis revealed no significant difference in 5-year OS between HR-HPV negative and HR-HPV positive groups (OS: 95.0% vs.95.6%, P=0.900). A significant difference was observed in 5-year DFS between the HR-HPV negative and HR-HPV positive groups (DFS: 87.2% vs.91.9%, P=0.025). Cox proportional hazard regression model indicated that HR-HPV infection (negative vs. positive) was an independent factor influencing 5-year DFS after early cervical cancer surgery (DFS: hazard ratio [HR]=1.862, P=0.022). HR-HPV infection (negative vs positive) was not an independent factor influencing 5-year OS after early cervical cancer surgery (OS: P=0.813). After 1:1 PSM pairing, there was no significant difference in 5-year OS and DFS between HR-HPV negative group and HR-HPV positive group (OS: 91.6% vs.95.0%, P=0.297; DFS: 87.2% vs.85.1%, P=0.758). Cox multivariate analysis indicated that HR-HPV infection was not an independent factor influencing 5-year OS and DFS after early cervical cancer surgery (OS: P=0.806, DFS: P=0.251).

Conclusions: The tumour results of HR-HPV negative group and HR-HPV positive group were similar, after eliminating the differences in known variables that affect the oncological outcomes of cervical cancer. The treatment plan of HR-HPV positive cervical cancer is suitable for HR-HPV negative cervical cancer.

References

Wang C, Lai C, Huang H, Chao A, Chang C, Chang T . Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy. Int J Radiat Oncol Biol Phys. 2010; 78(4):1111-20. DOI: 10.1016/j.ijrobp.2009.09.021. View

Fiacchini G, Benettini G, Trico D, Torregrossa L, Vianini M, Picariello M . Human papillomavirus-related head and neck adenosquamous carcinoma: A systematic review and individual patient data meta-analysis. Oral Oncol. 2021; 119:105252. DOI: 10.1016/j.oraloncology.2021.105252. View

Holl K, Nowakowski A, Powell N, McCluggage W, Pirog E, De Souza S . Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int J Cancer. 2015; 137(12):2858-68. PMC: 5034816. DOI: 10.1002/ijc.29651. View

Chen X, Zhang P, Chen S, Zhu H, Wang K, Ye L . Better or Worse? The Independent Prognostic Role of HPV-16 or HPV-18 Positivity in Patients With Cervical Cancer: A Meta-Analysis and Systematic Review. Front Oncol. 2020; 10:1733. PMC: 7577117. DOI: 10.3389/fonc.2020.01733. View

Chong G, Lee Y, Han H, Lee H, Park J, Hong D . Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer. Gynecol Oncol. 2017; 148(1):97-102. DOI: 10.1016/j.ygyno.2017.11.003. View

Li P, Tan Y, Zhu L, Zhou L, Zeng P, Liu Q . Prognostic value of HPV DNA status in cervical cancer before treatment: a systematic review and meta-analysis. Oncotarget. 2017; 8(39):66352-66359. PMC: 5630417. DOI: 10.18632/oncotarget.18558. View

Coussens L, Werb Z . Inflammation and cancer. Nature. 2002; 420(6917):860-7. PMC: 2803035. DOI: 10.1038/nature01322. View

Pirog E . Cervical Adenocarcinoma: Diagnosis of Human Papillomavirus-Positive and Human Papillomavirus-Negative Tumors. Arch Pathol Lab Med. 2017; 141(12):1653-1667. DOI: 10.5858/arpa.2016-0356-RA. View

Chen B, Ji M, Li P, Liu P, Zou W, Zhao Z . Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: A multicentre retrospective study. Gynecol Oncol. 2020; 157(2):429-436. DOI: 10.1016/j.ygyno.2020.02.019. View

10.

Kaliff M, Karlsson M, Sorbe B, Mordhorst L, Helenius G, Lillsunde-Larsson G . HPV-negative Tumors in a Swedish Cohort of Cervical Cancer. Int J Gynecol Pathol. 2019; 39(3):279-288. PMC: 7147426. DOI: 10.1097/PGP.0000000000000612. View

11.

Kaliff M, Sorbe B, Mordhorst L, Helenius G, Karlsson M, Lillsunde-Larsson G . Findings of multiple HPV genotypes in cervical carcinoma are associated with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated with radiotherapy. Oncotarget. 2018; 9(27):18786-18796. PMC: 5922355. DOI: 10.18632/oncotarget.24666. View

12.

Whiteside M, Siegel E, Unger E . Human papillomavirus and molecular considerations for cancer risk. Cancer. 2008; 113(10 Suppl):2981-94. DOI: 10.1002/cncr.23750. View

13.

Barreto C, Martins D, de Lima Filho J, Magalhaes V . Detection of human Papillomavirus in biopsies of patients with cervical cancer, and its association with prognosis. Arch Gynecol Obstet. 2013; 288(3):643-8. DOI: 10.1007/s00404-013-2803-2. View

14.

Li P, Liu P, Yang Y, Wang L, Liu J, Bin X . Hazard Ratio Analysis of Laparoscopic Radical Hysterectomy for IA1 With LVSI-IIA2 Cervical Cancer: Identifying the Possible Contraindications of Laparoscopic Surgery for Cervical Cancer. Front Oncol. 2020; 10:1002. PMC: 7360842. DOI: 10.3389/fonc.2020.01002. View

15.

Nichols A, Dhaliwal S, Palma D, Basmaji J, Chapeskie C, Dowthwaite S . Does HPV type affect outcome in oropharyngeal cancer?. J Otolaryngol Head Neck Surg. 2013; 42:9. PMC: 3650940. DOI: 10.1186/1916-0216-42-9. View

16.

Rossi P, Chini F, Bisanzi S, Burroni E, Carillo G, Lattanzi A . Distribution of high and low risk HPV types by cytological status: a population based study from Italy. Infect Agent Cancer. 2011; 6:2. PMC: 3038961. DOI: 10.1186/1750-9378-6-2. View

17.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

18.

Chen C, Wang W, Liu P, Li P, Wang L, Jin S . Survival After Abdominal Q-M Type B versus C2 Radical Hysterectomy for Early-Stage Cervical Cancer. Cancer Manag Res. 2020; 11:10909-10919. PMC: 6955639. DOI: 10.2147/CMAR.S220212. View

19.

Cuschieri K, Brewster D, Graham C, Nicoll S, Williams A, Murray G . Influence of HPV type on prognosis in patients diagnosed with invasive cervical cancer. Int J Cancer. 2014; 135(11):2721-6. DOI: 10.1002/ijc.28902. View

20.

Lei J, Arroyo-Muhr L, Lagheden C, Eklund C, Kleppe S, Elfstrom M . Human Papillomavirus Infection Determines Prognosis in Cervical Cancer. J Clin Oncol. 2022; 40(14):1522-1528. DOI: 10.1200/JCO.21.01930. View